Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02903160
Title Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Recruitment Completed
Gender male
Phase Phase II
Variant Requirements No
Sponsors Icahn School of Medicine at Mount Sinai

prostate adenocarcinoma


Abiraterone + Cabazitaxel + Carboplatin + Enzalutamide + Prednisone

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.